The result is a comparison of dose-response curves from LPS (the classic TLR4 agonist) and HMGB1. First, these results show that this product binds to and activates TLR4 (wells pre-treated with the TLR4 inhibitor CLI-095 showed no SEAP production data not shown). Second, it should be noted that this product is a less potent agonist than LPS, as evidenced by the curve being shifted to the right by about 2 orders of magnitude.
Abcam user community
Submitted Aug 03 2016